Shots:
- Roche has reported the global P-III (Krascendo 1) trial assessing divarasib monotx. (QD) vs sotorasib (QD) or adagrasib (BID) in 338 pts with previously treated KRAS G12C-mutant advanced or metastatic NSCLC
- The trial met its 1 & key 2EPs, with divarasib achieving improvements in both PFS & OS; data to be submitted to health authorities & presented at a future meeting
- Divarasib is also being evaluated in the P-III (Krascendo 2) trial with Keytruda for 1L KRAS G12C-mutant advanced NSCLC and P-III (Krascendo 3) trial as adj. monotx. for resected stage II–IIIB KRAS G12C-mutant NSCLC after SoC chemoimmunotherapy
Ref: Globenewswire | Image: Roche | Press Release
Related News: Roche’s Enspryng Receives the US FDA Priority Review for At-Home SC Treatment of Thyroid Eye Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
